ホーム › PubMed Lab 🤖 自分の AI で使う ⭐ 保存した論文

🔬 PubMed Lab

日本語で入力するだけで、PubMed の英語論文を検索できるリサーチアシスタントです。
卒論・研究テーマ探し、興味のある論文を効率よく見つけられます。

「腸内細菌ががん免疫療法の効果を左右する」の検索結果

2,239 件中 10 件を表示 (4614 ms) · ⭐ 保存した論文

AI が生成した英語クエリを見る
("Gastrointestinal Microbiome"[MeSH] OR "gut microbiota" OR "intestinal microbiome" OR "gut bacteria") AND ("Immunotherapy"[MeSH] OR "immunotherapy" OR "immune checkpoint inhibitors" OR "Cancer Vaccines"[MeSH]) AND ("Neoplasms"[MeSH] OR cancer OR tumor)

💡 腸内細菌、がん免疫療法をMeSH用語と同義語で組み合わせ、効果への影響を広く検索できるクエリを構築

🎓 卒論・修論テーマを AI が提案

この 5 本の論文を俯瞰して、あなたが実際に卒論・修論で研究できるテーマを 3 つ提案します。

残り 3 / 3 回 (今日)

📖 このサイトの解説記事から (日本語で読める)

PubMed Trivia が過去に取り上げた論文を日本語で解説している記事です。

🔍 PubMed の検索結果

  • Gastric Cancer, Immunotherapy, and Nutrition: The Role of Microbiota.

    Pauline Raoul, Valeria De Gaetano, Gianmario Sciaraffia 他 · Pathogens (Basel, Switzerland) · 2024

    Immune checkpoint inhibitors (ICI) have revolutionized the treatment of gastric cancer (GC), which still represents the third leading cause of cancer-related death in Western countries. However, ICI treatment outcomes vary between individuals and need to be optimized. Recent studies have shown that gut microbiota could represent a key influencer of immunotherapy responses. At the same time, the nu…

    📄 PubMed で読む (PMID: 38787209)
  • Microbiome and immunotherapy in bladder cancer: The missing link.

    Ali Bourgi, Franck Bruyère, Emmanuel Rusch 他 · The French journal of urology · 2025

    Bladder cancer remains a significant global health concern, with immunotherapies such as Bacillus Calmette-Guérin (BCG) and immune checkpoint inhibitors (ICIs) playing pivotal roles in treatment. Emerging evidence suggests that the microbiome, encompassing both gut and urinary tract microorganisms, may influence the efficacy and outcomes of these immunotherapies. This review aims to explore the in…

    📄 PubMed で読む (PMID: 40550271)
  • The Role of Gut Microbiome on Glioblastoma Oncogenesis and Malignant Evolution.

    Zaynab Sidi Mohamed, Qiong Wu, Maria A Jacome 他 · International journal of molecular sciences · 2025

    Glioblastoma (GBM) remains the most aggressive primary brain tumor, with poor survival outcomes and treatment limited to maximal safe surgical resection, chemotherapy with temozolomide, and radiotherapy. While immunotherapy and targeted treatments show promise, therapeutic resistance and disease progression remain major challenges. This is partly due to GBM's classification as a "cold tumor" with …

    📄 PubMed で読む (PMID: 40243570)
  • Lactobacillus salivarius potentiates gastrointestinal cancer immunotherapy through its metabolite chenodeoxycholic acid.

    Bohan Zhang, Yifan Zhang, Yi Cai 他 · Cell reports. Medicine · 2026

    Immune checkpoint inhibitor therapy has improved gastrointestinal (GI) cancer management; however, many patients exhibit resistance. Although gut microbiota influences immunotherapeutic responses, the underlying mechanisms remain unclear. Metagenomic analysis of 278 GI cancer patients reveals that Lactobacillus salivarius (L. salivarius) is enriched in responders and enhances anti-PD-1 efficacy in…

    📄 PubMed で読む (PMID: 42664954)
  • Global trends and emerging frontiers in cancer immunotherapy and gut microbiota-derived metabolites: a bibliometric analysis.

    Yingying Hu, Chenhuai Teng, Dian Zhang 他 · Frontiers in cellular and infection microbiology · 2026

    Cancer immunotherapy has achieved remarkable clinical success; however, therapeutic resistance remains a major challenge. Increasing evidence suggests that gut microbiota-derived metabolites play a critical role in modulating host immune responses and influencing treatment outcomes. This study aimed to systematically characterize the global research landscape and identify emerging trends in this f…

    📄 PubMed で読む (PMID: 42755487)
  • Gut microbiome-mediated modulation of the glioblastoma tumor microenvironment for enhanced immunotherapy response: Mechanistic insights and future perspectives.

    Urjaswee Dey, Lakshmi Priya Madabhushi, Amisha Anna Chacko 他 · Cellular signalling · 2026

    Glioblastoma (GBM) is known to be one of the most aggressive and deadly brain tumors in adults, with a very poor prognosis. An immunosuppressive tumor microenvironment, the blood-brain barrier's (BBB's) protective nature, and genetic heterogeneity mediate resistance to conventional treatments, such as immune checkpoint inhibitors. Recent studies have shed light on the important role of the gut-bra…

    📄 PubMed で読む (PMID: 42413643)
  • Crosstalk between the microbiome and immune microenvironment in the pathogenesis and treatment of thyroid carcinoma: a narrative review.

    Wanzhi Chen, Jichun Yu, Guoxue Fu 他 · Frontiers in immunology · 2026

    Thyroid carcinoma (TC) is the most common cancer of the endocrine system worldwide, and its incidence has remained stable over the past forty years. Complex hormonal and environmental factors influence TC progression. The gut microbiome, a pivotal mediator in maintaining host physiology and the development of pathology, serves as a biomarker and therapeutic target in cancer immunotherapy. The micr…

    📄 PubMed で読む (PMID: 42787629)
  • Beyond the barrier: Engineering the tumor-immune-soil nexus-a mechanistic blueprint for integrating Traditional Chinese Medicine with immunotherapy in metastatic colorectal cancer.

    Yu Sun, Yandong Li, Haopeng Jiang 他 · Medical oncology (Northwood, London, England) · 2026

    Metastatic colorectal cancer (mCRC) presents a stark immuno-oncologic dichotomy: while microsatellite instability-high (MSI-H) tumors respond to immune checkpoint inhibitors (ICIs), the vast majority of microsatellite-stable (MSS) cases remain refractory, underscoring a critical need for novel strategies to convert "cold" tumors into "hot" ones. This review advances the hypothesis that Traditional…

    📄 PubMed で読む (PMID: 42742786)
  • Baseline Gut Microbiota Composition Links Immune-nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study.

    Fumihiro Shoji, Sho Wakasu, Keisuke Kosai 他 · Anticancer research · 2026

    Immune-nutritional status and gut microbiota composition have been proposed as biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). However, their interrelationship and longitudinal dynamics during immunotherapy remain unclear. In this multicenter prospective study, patients with advanced or recurrent NSCLC treated with atezolizumab-based immunothera…

    📄 PubMed で読む (PMID: 42823161)
  • Precision editing of the gut microbiota ameliorates cancer immunotherapy.

    L Franza, V Carusi, G Parrinello 他 · Journal of biological regulators and homeostatic agents · 2019

    In this editorial the authors highlight recent findings which could help design a personalized approach for cancer immunotherapy.

    📄 PubMed で読む (PMID: 31833336)